Experiment Protocol Biomedical Engineer in Chile Santiago –Free Word Template Download with AI

This Experiment Protocol outlines the methodology for a clinical engineering study conducted in Santiago, Chile. Santiago, situated in the Central Valley at an altitude of approximately 520 meters, serves as a critical baseline for studying physiological responses before subjects ascend to higher altitudes in the Andes. The primary objective is to evaluate the accuracy and reliability of a novel wearable photoplethysmography (PPG) device designed by a team of Biomedical Engineers.

The study aims to compare the device's hemodynamic readings against standard invasive arterial line measurements in a controlled hospital environment within Santiago. This research is vital for developing robust monitoring tools for patients in remote regions of Chile where access to intensive care is limited.

Primary Objective: To determine the correlation coefficient between the novel wearable PPG device and invasive arterial blood pressure monitoring in adult patients.

Secondary Objectives:

• To assess the device's performance under varying ambient light conditions typical of Santiago's urban hospitals.
• To evaluate the comfort and usability of the device from the perspective of both patients and nursing staff.
• To ensure compliance with Chilean regulations regarding medical device testing and data privacy.

3.1 Study Design: This is a prospective, single-center, observational study.

3.2 Setting: The experiment will take place in the Intensive Care Unit (ICU) of a major public hospital in Santiago, Chile. The facility has been selected for its high volume of critical care patients requiring continuous hemodynamic monitoring.

3.3 Participants:

• Inclusion Criteria: Adults aged 18-75 years, admitted to the ICU, requiring invasive arterial monitoring for clinical reasons.
• Exclusion Criteria: Patients with severe peripheral vascular disease, skin conditions at the sensor site, or those unable to provide informed consent.

3.4 Procedure:

Upon obtaining informed consent, the Biomedical Engineer will calibrate the novel wearable device on the patient's index finger. Simultaneously, standard invasive arterial pressure monitoring will be maintained as per clinical protocol. Data will be collected continuously for 24 hours. The Biomedical Engineer will perform spot checks every 4 hours to ensure sensor integrity and data synchronization.

Data will be recorded using a secure, encrypted database hosted locally in Santiago to comply with Chilean data protection laws (Ley 19.628). The Biomedical Engineer will analyze the data using statistical software to calculate mean arterial pressure (MAP), systolic, and diastolic pressures. Bland-Altman plots will be generated to assess agreement between the two measurement methods.

This Experiment Protocol has been reviewed and approved by the Institutional Review Board (IRB) of the participating hospital in Santiago. The study adheres to the Declaration of Helsinki and local Chilean regulations for biomedical research. All participants will provide written informed consent. The Biomedical Engineer is responsible for ensuring that all data handling procedures respect patient confidentiality and anonymity.

Special attention is given to the ethical implications of testing new technology on vulnerable ICU patients. The device is non-invasive and poses no additional risk beyond standard care. In the event of any adverse events related to the device, the Biomedical Engineer must immediately halt data collection for that subject and report the incident to the IRB.

Biomedical Engineer: Responsible for device calibration, data integrity, technical troubleshooting, and final data analysis. The engineer must ensure that the device functions within specified safety parameters throughout the experiment.

Clinical Staff: Responsible for patient care, obtaining informed consent, and maintaining standard invasive monitoring.

Principal Investigator: Oversees the entire study, ensures regulatory compliance, and reports findings to stakeholders.

Potential risks include skin irritation from the wearable sensor and data transmission errors. Mitigation strategies include regular skin checks by nursing staff and redundant data storage systems. The Biomedical Engineer will conduct a pre-study safety audit of all equipment to minimize technical failures.

The study is scheduled to run for 6 months, beginning in November 2023 and concluding in April 2024. This timeline accounts for patient recruitment, data collection, analysis, and reporting phases.

This Experiment Protocol provides a comprehensive framework for validating a new biomedical device in a real-world clinical setting in Santiago, Chile. By adhering to strict ethical and technical standards, the Biomedical Engineer and research team aim to contribute valuable insights to the field of non-invasive monitoring, ultimately improving patient care in Chile and beyond.